Navigation Links
Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
Date:5/7/2012

SAN DIEGO, May 7, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Janet Roemer, Executive Vice President and Chief Operating Officer, will present at the upcoming Deutsche Bank Clean Tech, Utilities and Power Conference as part of the biofuels panel.  The panel is scheduled to begin at 2:15 p.m. ET on Monday, May 14, 2012 in New York City.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com


 

 


'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium Announces 2010 Business Update and Outlook for 2011
2. Verenium Announces Changes in Senior Management
3. Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
4. Verenium Corporation to Announce First Quarter 2011 Financial Results
5. Verenium Reports Financial Results for the First Quarter Ended March 31, 2011
6. Verenium to Host Analyst and Investor Day
7. Verenium Launches Second Enzyme Product for Oilfield Services
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Acute Myeloid Leukemia Drugs Price Analysis ... the global Acute Myeloid Leukemia market. This research will ... out how the marketed products for Acute Myeloid Leukemia are clinically ...
(Date:2/28/2017)... 2017 Prefilled Syringes Market: Scope and Segmentation ... This report provides a forecast and analysis ... and regional levels. It provides historical data of ... in terms of revenue (US$ Mn) and volume ... along with an outlook on prefilled syringes consumption ...
(Date:2/28/2017)... , Feb. 28, 2017 Summary ... to better understand Seattle Genetics and its partnering interests ... http://www.reportlinker.com/p03605624-summary/view-report.html Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
Breaking Medicine Technology:
(Date:3/1/2017)... NJ (PRWEB) , ... March 01, 2017 , ... ... Annual Miami Lung Cancer Conference® on April 8, 2017, in Sunny Isles Beach, ... chief executive officer, Massachusetts General Physicians Organization, Boston, and Dr. Heather Wakelee, associate ...
(Date:3/1/2017)... ... March 01, 2017 , ... RJ Young, the third largest independent ... Delchamps to Director of Integrated Solution Sales. Harris has been with RJ Young for ... , Harris will lead sales for the IT Services and Software divisions. He will ...
(Date:3/1/2017)... Colorado (PRWEB) , ... March 01, 2017 , ... ... announced the addition of Kara Richardson Whitely as a National Binge Eating Recovery Advocate. ... a highly skilled group of experts in their fields who speak at and attend ...
(Date:3/1/2017)... ... ... Financial Recovery Group, Inc. (FRG), is proud to announce it will participate as ... also is offering a special discount for those who attend the event as a ... brightest minds in the healthcare industry to share information on risk adjustment, quality management, ...
(Date:3/1/2017)... ... March 01, 2017 , ... The Industrial Designers Society of America ... raising awareness of the profession of industrial design (ID) and relaunching "What Is ... high school students and counselors; parents; and the greater public. , Share details and ...
Breaking Medicine News(10 mins):